Product Description
CPL-500036 is being developed by Celon Pharma SA for the treatment of patients with schizophrenia, medication-induced dyskinesia, and Parkinson's disease. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05297201?term=CPL-500036&draw=2&rank=1)
Mechanisms of Action: PDE10a Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Celon Pharma SA
Company Location:
Company CEO: Corinne Le Goff
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Hungary, Poland, Ukraine
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dyskinesia, Drug-Induced|Dyskinesias|Parkinson's Disease|Schizophrenia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05297201 |
03PDE2020 | P2 |
Completed |
Dyskinesia, Drug-Induced|Dyskinesias|Parkinson's Disease |
2025-01-13 |
50% |
2025-03-05 |
|
NCT05278156 |
02PDE2019 | P2 |
Completed |
Schizophrenia |
2024-06-05 |
12% |
2024-07-09 |
|
2020-006004-16 |
2020-006004-16 | P2 |
Completed |
Parkinson's Disease |
2025-01-27 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2020-002316-51 |
2020-002316-51 | P2 |
Completed |
Schizophrenia |
2024-06-19 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |